NetScientific PLC Subsidiary, Glycotest collaboration with Oncimmune (3461T)
03 Outubro 2014 - 3:00AM
UK Regulatory
TIDMNSCI
RNS Number : 3461T
NetScientific PLC
03 October 2014
NetScientific plc
('NetScientific' or 'the Group')
NetScientific's subsidiary, Glycotest Begins a
New Research Collaboration with Oncimmune
Application of Combined Diagnostic Technologies Aimed at
Improving
Early Detection of Liver Cancer
3 October 2014: NetScientific (AIM: NSCI), the global biomedical
and healthcare technology group today announces its portfolio
company Glycotest, Inc. has entered into a research collaboration
with Oncimmune Ltd to explore the combined application of their
proprietary tests in the early detection of liver cancer.
Oncimmune has previously commercialised its proprietary
autoantibody assay technology for the early detection of lung
cancer with its EarlyCDT-Lung test and is now expanding this
technology to the detection of liver cancer as well as other solid
tumour cancers. Glycotest is developing proprietary glycoprotein
biomarkers and assay technology for the surveillance of serious
liver diseases, including liver cancer.
Liver cancer and chronic liver disease are global,
life-threatening health issues that arise from chronic conditions
such as non-alcoholic steatohepatitis (NASH), hepatitis B and C
infections. Each year more than 500,000 people die from liver
cancer, the second leading cause of cancer deaths. Early detection
of liver cancer at a potentially curable stage remains an unmet
diagnostic need.
Under the terms of the agreement, Glycotest and Oncimmune will
conduct a joint clinical evaluation of their combined tests, which
could then be co-developed as agreed by the collaborators.
Sir Richard Sykes, Chairman of NetScientific, said, "Today's
announcement marks a key point in the validation of the Glycotest
technology from the wider scientific community, and mirrors our
statement at the recent half year results, that our subsidiaries
are making significant progress. Working closely with Oncimmune, we
believe that Glycotest will make a meaningful contribution to this
pioneering collaboration and look forward to updating shareholders
further in due course."
Geoffrey Hamilton-Fairley, CEO of Oncimmune, added: "We believe
that the most clinically valid and cost effective way to address
the early detection of cancer is via two routes; through the
further development of our proprietary autoantibody technology and
its combination with other complementary technologies. We view
Glycotest's biomarkers as potentially complementary and we are
excited about collaborating with the team."
-Ends-
About NetScientific
NetScientific is a global biomedical and healthcare technology
groupthat funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment. For more information, please visit the
website at www.netscientific.net.
About Glycotest
Glycotest, Inc., founded by NetScientific plc, is a spin out of
the Philadelphia, Pennsylvania area institutions Drexel University
College of Medicine and the Baruch S. Blumberg Institute. Glycotest
is commercializing new diagnostic tests for the growing liver
cancer market.
About Oncimmune
Oncimmune Ltd, based in Nottingham, UK, is committed to
advancing early cancer detection through proprietary autoantibody
assay technologies based on technology initially identified at
Nottingham University. Oncimmune Ltd.'s mission is to develop early
cancer detection tests to identify more than 90 percent of
solid-tumor cancers.
Contact Details
NetScientific plc Tel: +44 (0) 20 3290
Farad Azima 8877
Peter Thoms
Liberum (NOMAD and Broker) Tel: +44 (0)20 3100 2000
Chris Bowman / Christopher Britton
/ Thomas Bective
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Tim Watson 2020
Email: netscientific@instinctif.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCMMMGGVZFGDZM
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024